This bill proposes to amend the Public Health Service Act to restrict how healthcare providers participating in the 340B drug pricing program can utilize their generated savings. It specifically prohibits 340B covered entities from using funds derived from the difference between the 340B ceiling price and the actual acquisition cost of covered outpatient drugs for certain medical services. The legislation defines these restricted services as "services described," which include sex reassignment surgeries and hormone treatments furnished for the purpose of gender alteration of a transgender individual. By implementing this prohibition, the bill aims to prevent federal drug discount savings from being allocated to these specific types of care. This amendment would directly impact the financial operations of 340B covered entities regarding their provision of transgender-related medical services.